Biotech & Healthcare: Rocket Pharmaceuticals (Cranbury) says early safety is promising in its RP-A501 Danon disease Phase 2 trial, with no major safety issues seen in the first three patients and plans to align with the FDA on the next dosing pathway. M&A Watch: Curium and Lantheus announced a definitive merger deal worth up to $8.0B, combining radiopharmaceutical theranostics and manufacturing with Lantheus’ U.S. radiodiagnostics business. Life Sciences Access: FDA approval expands Pluvicto for earlier-stage metastatic prostate cancer, but delivery still depends on licensed nuclear medicine centers. Pharma Markets: AstraZeneca shares slid after reports of early merger talks with Bristol Myers Squibb, a potential ~$400B combination. Energy & Data Centers: Exelon reported its “high probability” data center load fell nearly 40% to about 11 GW, as transmission security agreements filter out speculative projects. Environment: BioLargo says its PFAS-removal AEC system has treated more than 2 million gallons at its Lake Stockholm, NJ reference site, meeting state and EPA standards. Construction & Infrastructure: Skanska USA won a $93M Newark Dock Bridge rehabilitation project tied to the Gateway Program. Weather: Flooding returned to North Jersey with multiple road closures and rescues as heavy rain hit the region. Real Estate/Local Business: Edible Garden expanded a multi-year private label supply agreement with a major Midwest big-box retailer through Dec. 31, 2028.